# US 2001/0033857 A1 · Porous tissue scaffoldings for the repair or regeneration of tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0033857 A1
- Document ID: US20010033857A1
- Status: Published application
- Kind: A1
- Application number: 09/740,086
- Filed: 2000-12-19
- Published: 2001-10-25
- Earliest claimed: 1999-06-30
- Assignees: Ethicon, Inc.
- Inventors: Murty N. Vyakarnam; Mark C. Zimmerman; Angelo George Scopelianos; Mark B. Roller; David V. Gorky
- Web page: https://patentgrep.com/patent/US20010033857A1

## CPC

- A61L 27/3817: {Cartilage-forming cells, e.g. pre-chondrocytes}
- A61F 2/28: Bones
- A61F 2/30756: {Cartilage endoprostheses (A61F2/3603 takes precedence)}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- A61F 2/06: Blood vessels
- A61F 2002/30004: {the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis}
- A61F 2002/30011: {differing in porosity}
- A61F 2002/30014: {differing in elasticity, stiffness or compressibility}
- A61F 2002/30032: {differing in absorbability or resorbability, i.e. in absorption or resorption time}
- A61F 2002/30062: {(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive}
- A61F 2002/30677: {Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body}
- A61F 2002/30766: {Scaffolds for cartilage ingrowth and regeneration}
- A61F 2002/30784: {Plurality of holes}
- A61F 2002/3092: {having an open-celled or open-pored structure}
- A61F 2210/0004: bioabsorbable
- A61F 2250/0014: having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F 2250/0018: differing in elasticity, stiffness or compressibility
- A61F 2250/0023: differing in porosity
- A61F 2250/0029: differing in bending or flexure capacity
- A61F 2250/003: differing in adsorbability or resorbability, i.e. in adsorption or resorption time
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- Y10S 623/915: Method or apparatus for preparing biological material
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present patent describes a three-dimensional interconnected open cell porous foams that have a gradient in composition and/or microstructure through one or more directions. These foams can be made from a blend of absorbable and biocompatible polymers that are formed into foams having a compositional gradient transitioning from predominately one polymeric material to predominately a second polymeric material. These gradient foams are particularly well suited to tissue engineering applications and can be designed to mimic tissue transition or interface zones.

## Claims

### Claim 1

A biocompatible gradient foam comprising a biocompatible gradient foam having a first location and a second location wherein the biocompatible gradient foam has a substantially continuous transition in at least one characteristic selected from the group consisting of composition, stiffness, flexibility, bioabsorption rate and pore architecture from the first location to the second location of said biocompatible gradient foam.

### Claim 2 (depends on 1)

The biocompatible gradient foam of claim 1 wherein the biocompatible gradient foam is bioabsorbable.

### Claim 3 (depends on 1)

The biocompatible gradient foam of claim 1 wherein the biocompatible gradient foam is made from a bioabsorbable polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups poly(anhydrides), polyphosphazenes, biopolymers and blends thereof.

### Claim 4 (depends on 3)

The biocompatible gradient foam of claim 3 wherein the bioabsorable polymer is an aliphatic polyester.

### Claim 5 (depends on 4)

The biocompatible gradient foam of claim 4 wherein the aliphatic polyester is selected from the group consisitng of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

### Claim 6 (depends on 3)

The biocompatible gradient foam of claim 3 wherein the aliphatic polyester is an elastomer.

### Claim 7 (depends on 5)

The biocompatible gradient foam of claim 5 wherein the elastomer is selected from the group consisting of copolymers of ε-caprolactone and glycolide; copolymers of ε-caprolactone and (L) lactide, copolymers of p-dioxanone (1,4-dioxan-2-one) and (L) lactide, copolymers of ε-caprolactone and p-dioxanone, copolymers of p-dioxanone and trimethylene carbonate, copolymers of trimethylene carbonate and glycolide, copolymer of trimethylene carbonate and (L) lactide and blends thereof.

### Claim 8 (depends on 4)

The biocompatible gradient foam of claim 4 wherein additionally present as a constituent of the biocompatible gradient foam is a second aliphatic polyester.

### Claim 9 (depends on 3)

The biocompatible gradient foam of claim 3 wherein the biocompatible gradient foam has a substantially continuous transition in composition from the first location to the second location.

### Claim 10 (depends on 9)

The biocompatible gradient foam of claim 9 wherein the biocompatible gradient foam has a substantially continuous transition in composition from a first ratio of at least two different aliphatic polyesters to a second ratio of said at least two different aliphatic polyesters from the first surface to the second surface.

### Claim 11 (depends on 3)

The biocompatible gradient foam of claim 3 wherein the biocompatible gradient foam has a substantially continuous transition in stiffness from the first location to the second location.

### Claim 12 (depends on 3)

The biocompatible gradient foam of claim 3 wherein the biocompatible gradient foam has a substantially continuous transition in bioabsorption rate from the first location to the second location.

### Claim 13 (depends on 3)

The biocompatible gradient foam of claim 3 wherein the biocompatible gradient foam has a substantially continuous transition in flexibility from the first location to the second location.

### Claim 14 (depends on 3)

The biocompatible gradient foam of claim 3 wherein the biocompatible gradient foam has a substantially continuous transition in architecture from the first location to the second location.

### Claim 15 (depends on 14)

The biocompatible gradient foam of claim 14 wherein the biocompatible gradient foam has a substantially continuous transition in architecture from a substantially spherical pore shape to a columnar pore shape from the first location to the second location.

### Claim 16 (depends on 14)

The biocompatible gradient foam of claim 14 wherein the substantially spherical pore's size is from about 30 μm to about 150 μm.

### Claim 17 (depends on 14)

The biocompatible gradient foam of claim 14 wherein the columnar pore's diameter is from about 100 μm to about 400 μm with a length to diameter ratio of at least 2.

### Claim 18 (depends on 1)

The biocompatible gradient foam of claim 1 wherein also present in the biocompatible gradient foam is a therapeutic agent.

### Claim 19 (depends on 1)

The biocompatible gradient foam of claim 1 wherein additionally present is an agent is selected from the group consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents prostaglandins, RDG peptides and combinations thereof.

### Claim 20 (depends on 19)

The biocompatible gradient foam of claim 19 wherein the growth factor is selected from the group consisting of bone morphogenic proteins, bone morphogenic-like proteins, epidermal growth factor, fibroblast growth factors, platelet derived growth factor, insulin like growth factor, transforming growth factors, vascular endothelial growth factor and combinations thereof.

### Claim 21 (depends on 1)

The biocompatible gradient foam of claim 1 wherein the biocompatible gradient foam is filled with a biocomptible material selected from the group consisting of bioabsorbable synthetic polymers, biocompatible, bioabsorbable biopolymers, biocompatible ceramic materials and combinations thereof.

### Claim 22

A biocompatible foam comprising a biocompatible foam having a first surface and a second surface with interconnecting pores and channels.

### Claim 23 (depends on 22)

The biocompatible foam of claim 22 wherein the channels have an average length of at least 200 μm.

### Claim 24 (depends on 22)

The biocompatible foam of claim 22 wherein the channels extend substantially from said first surface to said second surface.

### Claim 25 (depends on 22)

The biocompatible foam of claim 22 wherein the biocompatible foam is bioabsorbable.

### Claim 26 (depends on 22)

The biocompatible foam of claim 22 wherein the biocompatible foam is made from a bioabsorbable polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups poly(anhydrides), polyphosphazenes, biopolymers and blends thereof.

### Claim 27 (depends on 26)

The biocompatible foam of claim 26 wherein the bioabsorable polymer is an aliphatic polyester.

### Claim 28 (depends on 27)

The biocompatible foam of claim 27 wherein the aliphatic polyester is selected from the group consisitng of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

### Claim 29 (depends on 26)

The biocompatible foam of claim 26 wherein the aliphatic polyester is an elastomer.

### Claim 30 (depends on 29)

The biocompatible foam of claim 29 wherein the elastomer is selected from the group consisting of copolymers of ε-caprolactone and glycolide; copolymers of ε-caprolactone and (L) lactide, copolymers of p-dioxanone (1,4-dioxan-2-one) and (L) lactide, copolymers of ε-caprolactone and p-dioxanone, copolymers of p-dioxanone and trimethylene carbonate, copolymers of trimethylene carbonate and glycolide, copolymer of trimethylene carbonate and (L) lactide and blends thereof.

### Claim 31 (depends on 27)

The biocompatible foam of claim 27 wherein additionally present as a constituent of the foam is a second aliphatic polyester.

### Claim 32 (depends on 26)

The biocompatible foam of claim 26 wherein the biocompatible foam has a substantially continuous transition in composition from the first surface to the second surface.

### Claim 33 (depends on 32)

The biocompatible foam of claim 32 wherein the biocompatible foam has a substantially continuous transition in composition from a first ratio of at least two different aliphatic polyesters to a second ratio of said at least two different aliphatic polyesters from the first surface to the second surface.

### Claim 34 (depends on 26)

The biocompatible foam of claim 26 wherein the biocompatible foam has a substantially continuous transition in stiffness from the first surface to the second surface.

### Claim 35 (depends on 26)

biocompatible foam of claim 26 wherein the biocompatible foam has a substantially continuous transition in bioabsorption rate from the first surface to the second surface.

### Claim 36 (depends on 26)

The biocompatible foam of claim 26 wherein the biocompatible foam has a substantially continuous transition in flexibility from the first surface to the second surface.

### Claim 37 (depends on 26)

The biocompatible foam of claim 26 wherein the biocompatible foam has a substantially continuous transition in architecture from the first surface to the second surface.

### Claim 38 (depends on 37)

The biocompatible foam of claim 37 wherein the subsantially spherical pore's size is from about 30 μm to about 150 μm.

### Claim 39 (depends on 22)

The biocompatible foam of claim 22 wherein also present in the biocompatible foam is a therapeutic agent.

### Claim 40 (depends on 22)

The biocompatible foam of claim 22 wherein additonally present is an agent selected from the group consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.

### Claim 41 (depends on 40)

The biocompatible foam of claim 40 wherein the growth factor is selected from the group consisting of bone morphogenic proteins, bone morphogenic-like proteins, epidermal growth factor, fibroblast growth factors, platelet derived growth factor, insulin like growth factor, transforming growth factors, vascular endothelial growth factor and combinations thereof.

### Claim 42 (depends on 22)

The biocompatible foam of claim 22 wherein the biocompatible foam is filled with a biocomptible material selected from the group consisting of bioabsorbable synthetic polymers, biocompatible, bioabsorbable biopolymers, biocompatible ceramic materials and combinations thereof.

### Claim 43

A biocompatible foam comprising a biocompatible foam having interconnected pores formed from a composition containing in the range of from about 30 weight percent to about 99 weight percent ε-caprolactone repeating units.

### Claim 44 (depends on 43)

The biocompatible foam of claim 43 wherein the ε-caprolactone repeating units are copolymerized with a comonomer selected from the group consisting of lactide, lactic acid, glycolide, glycolic acid), p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

### Claim 45 (depends on 43)

The biocompatible foam of claim 43 having a first location and a second location wherein the biocompatible foam has a substantially continuous transition in at least one characteristic selected from the group consisting of composition, stiffness, flexibility, bioabsorption rate and pore architecture from the first location to the second location of said biocompatible foam.

### Claim 46 (depends on 43)

The biocompatible foam of claim 43 wherein the interconnecting pores have a pore size in the range from about 10 μm to about 200 μm.

### Claim 47 (depends on 43)

The biocompatible foam of claim 43 wherein the biocompatible foam has a porosity of in the range of from about 20 to about 98 percent.

### Claim 48 (depends on 43)

The biocompatible foam of claim 43 wherein the biocompatible foam has channels.

### Claim 49 (depends on 48)

The biocompatible foam of claim 48 wherein the channels have an average length of at least 200 μm.

### Claim 50 (depends on 43)

The biocompatible foam of claim 43 wherein additionally present as a constituent of the biocompatible foam is a second aliphatic polyester.

### Claim 51 (depends on 45)

The biocompatible foam of claim 45 wherein the biocompatible foam has a substantially continuous transition in composition from the first location to the second location.

### Claim 52 (depends on 51)

The biocompatible foam of claim 51 wherein the biocompatible foam has a substantially continuous transition in composition from a first ratio of at least two different aliphatic polyesters to a second ratio of said at least two different aliphatic polyesters from the first location to the second location.

### Claim 53 (depends on 45)

The biocompatible foam of claim 45 wherein the biocompatible foam has a substantially continuous transition in stiffness from the first location to the second location.

### Claim 54 (depends on 45)

The biocompatible foam of claim 45 wherein the biocompatible foam has a substantially continuous transition in bioabsorption rate from the first location to the second location.

### Claim 55 (depends on 45)

The biocompatible foam of claim 45 wherein the biocompatible foam has a substantially continuous transition in flexibility from the first location to the second location.

### Claim 56 (depends on 45)

The biocompatible foam of claim 45 wherein the biocompatible foam has a substantially continuous transition in architecture from the first location to the second location.

### Claim 57 (depends on 56)

The biocompatible foam of claim 56 wherein the biocompatible foam has a substantially continuous transition in architecture from a substantially spherical pore shape to a columnar pore shape from the first location to the second location.

### Claim 58 (depends on 56)

The biocompatible foam of claim 56 wherein the substantially spherical pore's size is from about 30 μm to about 150 μm.

### Claim 59 (depends on 56)

The biocompatible foam of claim 56 wherein the columnar pore's diameter is from about 30 μm to about 400 μm with a length to diameter ratio of at least 2.

### Claim 60 (depends on 43)

The biocompatible foam of claim 43 wherein also present in the biocompatible foam is a therapeutic agent.

### Claim 61 (depends on 43)

The biocompatible foam of claim 43 wherein additionally present is an agent selected from the group consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.

### Claim 62 (depends on 61)

The biocompatible foam of-claim 61 wherein the growth factor is selected from the group consisting of bone morphogenic proteins, bone morphogenic-like proteins, epidermal growth factor, fibroblast growth factors, platelet derived growth factor, insulin like growth factor, transforming growth factors, vascular endothelial growth factor and combinations thereof.

### Claim 63 (depends on 43)

The biocompatible foam of claim 43 wherein the biocompatible foam is filled with a biocomptible material selected from the group consisting of bioabsorbable synthetic polymers, biocompatible, bioabsorbable biopolymers, biocompatible ceramic materials and combinations thereof.

### Claim 64 (depends on 1)

The biocompatible gradient foam of claim 1 wherein the biocompatible gradient foam is formed with an insert within the biocompatible gradient foam.

### Claim 65 (depends on 64)

The biocompatible gradient foam of claim 64 wherein the insert is selected from the group consisting of films, scrims, woven textiles, knitted textiles, braided textiles, orthopedic implants, tubes and combinations thereof.

### Claim 66 (depends on 22)

The biocompatible gradient foam of claim 22 wherein the biocompatible foam is formed with an insert within the biocompataible foam.

### Claim 67 (depends on 66)

The biocompatible foam of claim 66 wherein the insert is selected from the group consisting of films, scrims, woven textiles, knitted textiles, braided textiles, orthopedic implants, tubes and combinations thereof.

### Claim 68 (depends on 43)

The biocompatible foam of claim 43 wherein the biocompatible foam is formed with an insert within the biocompatible foam.

### Claim 69 (depends on 68)

The biocompatible foam of claim 68 wherein the insert is selected from the group consisting of films, scrims, woven textiles, knitted textiles, braided textiles, orthopedic implants, tubes and combinations thereof.

### Claim 70 (depends on 1)

The biocompatible gradient foam of claim 1 wherein the biocompatible gradient foam is formed into a three-dimensional shaped structure.

### Claim 71 (depends on 70)

The biocompatible gradient foam of claim 70 wherein the three-dimensional shaped structure is selected from the group consisting of tubular shapes, branched tubular shapes, spherical shapes, hemispherical shapes, three-dimensional polygonal shapes, ellipsoidal shapes, toroidal shapes, conical shapes, frusta conical shapes, pyramidal shapes, both as solid and hollow constructs and combination thereof.

### Claim 72 (depends on 22)

The biocompatible foam of claim 22 wherein the biocompatible foam is formed into a three-dimensional shaped structure.

### Claim 73 (depends on 72)

The biocompatible foam of claim 72 wherein the three-dimensional shaped structure is selected from the group consisting of tubular shapes, branched tubular shapes, spherical shapes, hemispherical shapes, three-dimensional polygonal shapes, ellipsoidal shapes, toroidal shapes, conical shapes, frusta conical shapes, pyramidal shapes, both as solid and hollow constructs and combination thereof.

### Claim 74 (depends on 43)

The biocompatible foam of claim 43 wherein the biocompatible foam is formed into a three-dimensional shaped structure.

### Claim 75 (depends on 74)

The biocompatible foam of claim 74 wherein the three-dimensional shaped structure is selected from the group consisting of tubular shapes, branched tubular shapes, spherical shapes, hemispherical shapes, three-dimensional polygonal shapes, ellipsoidal shapes, toroidal shapes, conical shapes, frusta conical shapes, pyramidal shapes, both as solid and hollow constructs and combination thereof.

### Claim 76

A method for the repair or regeneration of tissue comprising contacting cells with a biocompatible gradient foam having a biocompatible gradient foam having a first location and a second location wherein the biocompatible gradient foam has a substantially continuous transition in at least one characteristic selected from the group consisting of composition, stiffness, flexibility, bioabsorption rate and pore architecture from the first location to the second location of said biocompatible gradient foam.

### Claim 77 (depends on 76)

The method of claim 76 wherein the biocompatible gradient foam is bioabsorbable.

### Claim 78 (depends on 76)

The method of claim 76 wherein the biocompatible gradient foam is made from a bioabsorbable polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, poly (iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups poly(anhydrides), polyphosphazenes, biopolymers and blends thereof.

### Claim 79 (depends on 78)

The method foam of claim 78 wherein the bioabsorable polymer is an aliphatic polyester.

### Claim 80 (depends on 79)

The method foam of claim 79 wherein the aliphatic polyester is selected from the group consisting of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

### Claim 81 (depends on 80)

The biocompatible gradient foam of claim 80 wherein the aliphatic polyester is an elastomer.

### Claim 82 (depends on 76)

The method of claim 76 wherein cells are seeded onto the biocompatible gradient foam.

### Claim 83 (depends on 80)

The method of claim 80 wherein cells are seeded onto the biocompatible gradient foam.

### Claim 84 (depends on 76)

The method of claim 76 wherein the biocompatible gradient foam is implanted in an animal and contacted with cells.

### Claim 85 (depends on 80)

The method of claim 80 wherein the biocompatible gradient foam is implanted in an animal and contacted with cells.

### Claim 86 (depends on 76)

The method of claim 76 wherein the biocompatible gradient foam is seeded with cells and the biocompatible gradient foam and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible gradient foam.

### Claim 87 (depends on 80)

The method of claim 80 wherein the biocompatible gradient foam is seeded with cells and the biocompatible gradient foam and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible gradient foam.

### Claim 88 (depends on 80)

The method of claim 80 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.

### Claim 89 (depends on 80)

The method of claim 80 wherein the cells are selected from the group consisting of myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.

### Claim 90 (depends on 82)

The method of claim 82 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.

### Claim 91 (depends on 82)

The method of claim 82 wherein the cells are selected from the group consisting of myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.

### Claim 92 (depends on 76)

The method of claim 76 wherein the biocompatible gradient foam contains an agent selected from the group consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.

### Claim 93

A method for the repair or regeneration of tissue comprising contacting cells with a biocompatible foam having a first surface and a second surface with interconnecting pores and channels.

### Claim 94 (depends on 93)

The method of claim 93 wherein the biocompatible foam is bioabsorbable.

### Claim 95 (depends on 93)

The method of claim 93 wherein the biocompatible foam is made from a bioabsorbable polymer selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups poly(anhydrides), polyphosphazenes, biopolymers and blends thereof.

### Claim 96 (depends on 95)

The method of claim 95 wherein the bioabsorable polymer is an aliphatic polyester.

### Claim 97 (depends on 96)

The method of claim 96 wherein the aliphatic polyester is selected from the group consisting of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

### Claim 98 (depends on 97)

The method of claim 97 wherein the aliphatic polyester is an elastomer.

### Claim 99 (depends on 93)

The method of claim 93 wherein cells are seeded onto the biocompatible foam.

### Claim 100 (depends on 97)

The method of claim 97 wherein cells are seeded onto the biocompatible foam.

### Claim 101 (depends on 93)

The method of claim 93 wherein the biocompatible foam is implanted in an animal and contacted with cells.

### Claim 102 (depends on 97)

The method of claim 97 wherein the biocompatible foam is implanted in an animal and contacted with cells.

### Claim 103 (depends on 93)

The method of claim 93 wherein the biocompatible foam is seeded with cells and the biocompatible foam and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible foam.

### Claim 104 (depends on 97)

The method of claim 97 wherein the biocompatible foam is seeded with cells and the biocompatible foam and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible foam.

### Claim 105 (depends on 97)

The method of claim 97 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.

### Claim 106 (depends on 97)

The method of claim 97 wherein the cells are selected from the group consisting of myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.

### Claim 107 (depends on 99)

The method of claim 99 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.

### Claim 108 (depends on 99)

The method of claim 99 wherein the cells are selected from the group consisting of myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct silo cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.

### Claim 109 (depends on 93)

The method of claim 93 wherein the biocompatible foam contains an agent selected from the group consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.

### Claim 110

A method for the repair or regeneration of tissue comprising contacting cells with a biocompatible having interconnected pores formed from a composition containing in the range of from about 30 weight percent to about 99 weight percent ε-caprolactone repeating units.

### Claim 111 (depends on 110)

The method foam of claim 110 wherein the ε-caprolactone repeating units are polymerized with a comonomer selected from the group consisting of homopolymers and copolymers of lactide, lactic acid, glycolide, glycolic acid), p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, δ-valerolactone, β-butyrolactone, γ-butyrolactone, ε-decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one, 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one, 6,6-dimethyl-1,4-dioxan-2-one and polymer blends thereof.

### Claim 112

The biocompatible gradient foam of claim ill wherein the aliphatic polyester is an elastomer.

### Claim 113 (depends on 110)

The method of claim 110 wherein cells are seeded onto the biocompatible foam.

### Claim 114 (depends on 111)

The method of claim 111 wherein cells are seeded onto the biocompatible foam.

### Claim 115 (depends on 110)

The method of claim 110 wherein the biocompatible foam is implanted in an animal and contacted with cells.

### Claim 116 (depends on 111)

The method of claim 111 wherein the biocompatible foam is implanted in an animal and contacted with cells.

### Claim 117 (depends on 110)

The method of claim 110 wherein the biocompatible foam is seeded with cells and the biocompatible foam and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible foam.

### Claim 118 (depends on 111)

The method of claim 111 wherein the biocompatible gradient foam is seeded with cells and the biocompatible foam and cells are placed in a cell culturing device and the cells are allowed to multiply on the biocompatible foam.

### Claim 119 (depends on 110)

The method of claim 110 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.

### Claim 120 (depends on 110)

The method of claim 110 wherein the cells are selected from the group consisting of myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.

### Claim 121 (depends on 110)

The method of claim 110 wherein the cells are selected from the group consisting of pluripotent cells, stem cells, precursor cells and combinations thereof.

### Claim 122 (depends on 111)

The method of claim 111 wherein the cells are selected from the group consisting myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells and combinations thereof.

### Claim 123 (depends on 110)

The method of claim 110 wherein the biocompatible gradient foam contains an agent selected from the group consisting of antiinfectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RDG peptides and combinations thereof.

### Claim 124 (depends on 86)

The method of claim 86 wherein after the cells are allowed to multiply on the biocompatible foam, the biocompatible foam and the cells are implanted into an animal.

### Claim 125 (depends on 103)

The method of claim 103 wherein after the cells are allowed to multiply on the biocompatible foam, the biocompatible foam and the cells are implanted into an animal.

### Claim 126 (depends on 118)

The method of claim 118 wherein after the cells are allowed to multiply on the biocompatible foam, the biocompatible foam and the cells are implanted into an animal.
